Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
VBI Vaccines (VBIV) has issued an update.
VBI Vaccines Inc. has engaged with H.C. Wainwright & Co. to potentially sell up to $8,468,289 worth of common shares in an at-the-market offering, following a registration statement effective since September 2022. The company could use the proceeds for general corporate purposes, with Wainwright earning a 3% commission on sales. This new agreement follows the termination of a previous arrangement with Jefferies LLC, which could have seen sales up to $125 million, and carries no penalties for the company.
See more data about VBIV stock on TipRanks’ Stock Analysis page.